Area of Interest Immuno-Oncology Immuno-Oncology with Microfluidics

Bringing Immuno-Oncology into Focus 

Advanta IO Gene Expression Assay and Workflow 

Tumor gene expression has proven effective in measuring immune response in cancer progression and therapeutic response research. As emerging therapies reveal new biomarkers and expand the need for samples, the costs and labor required to complete this important work also rise. Cancer researchers now have a reliable, sensitive and cost-effective toolset for identifying gene expression signatures from immune and cancer cells: the Advanta™ IO Gene Expression Assay, used with the Biomark™ HD system. 

Blue icon illustrating immuno-oncology application

A powerful immuno-oncology focused assay 

The Advanta IO Gene Expression Assay was developed in collaboration with leading researchers in the biopharmaceutical industry to provide the right balance of biomarker breadth, assay flexibility and workflow efficiency. 

The panel consists of 170 genes, including 91 reported in Nature, where Roy Herbst et al. defined a gene set representing tumor and immune response. The panel includes markers for: 

  • Immune cell identification 
  • Immune and cancer cell function 
  • Immune regulation and cell fate 
  • Checkpoint therapy response 

Optimized for FFPE and fresh frozen tumor samples, the Advanta IO Gene Expression Assay uses TaqMan® chemistry to sensitively measure gene expression, with five reference genes serving as analysis controls. Combined with Fluidigm microfluidics technology, the assay uniquely offers significant workflow efficiencies over traditional gene expression profiling methods. Each reaction is miniaturized to nanoliter volume and controlled using precise automation to empower accurate and cost-effective qPCR analysis across a large dynamic range. Since assay introduction into the integrated fluidic circuit (IFC) is under user control, researchers also have the flexibility to add up to 17 new assays or exchange gene assays within the panel to achieve experimental goals—all without affecting the original panel content, protocol or workflow. 

Download the flyer to learn more about the Advanta IO Gene Expression Assay workflow using the Biomark HD system, and to see the list of gene expression targets covered in the assay. 

Sample case study 

In a 2016 paper published by The Lancet for the POPLAR study, “Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer,” Louis Fehrenbacher et al. used immunohistochemistry, and also ran a gene expression panel of 91 genes featured in the Herbst paper. These genes are included in the Advanta IO Gene Expression Assay.  

The team subsequently used these research results to develop a gene signature based on a subset of the panel, that provided data that could potentially be used for developing future diagnostics tests. 

Publications

Powering over 1,500 scientific publications with our products

VIEW ALL

Melissa Davis, PhD

Spotlight IMC MELISSA DAVIS

Defining spatial characteristics using Imaging Mass Cytometry

Bernd Bodenmiller, PhD

Spotlight IMC Bodenmiller

Bernd Bodenmiller on revealing new insights into tumors with Imaging Mass Cytometry

David L. Rimm, MD, PhD

Spotlight IMC David Rimm

David Rimm on the value of Imaging Mass Cytometry for immunology applications at Yale

Sonia Gavasso, PhD

Spotlight MC Sonia Gavasso

Sonia Gavasso on the potential for mass cytometry to improve immunotherapy

Ansuman Satpathy, MD, PhD

Spotlight MF Ansu Satpathy

Stanford’s Ansu Satpathy designed single-cell T-ATAC-seq, now available at Script Hub

Evan Newell, PhD

Spotlight MC EVAN NEWELL

Evan Newell on decoding immune cell heterogeneity with mass cytometry

Wendy Fantl, PhD

Spotlight MC Fantl Wendy

On the right path to better ovarian cancer diagnosis and treatment

Corinne Ramos, PhD, MBA

Spotlight IMC Corinne Ramos

A discussion with Corinne Ramos, MBA, PhD

Shyam Prabhakar, PhD

Spotlight MC SHYAM PRABHAKAR

Shyam Prabhakar explores signatures of patient survival and EMT in colorectal tumors

Dr. Dexi Chen, PhD, MD

Spotlight IMC DR. DEXI CHEN

Achieving multi-omic insights with microfluidics and CyTOF technology

Scott Magness, PhD

Spotlight MF SCOTT MAGNESS

Investigating transcriptomic changes at the microscale level

Dr. Luc Teyton, MD, PhD

Spotlight MC DR. LUC TEYTON

How one lab explores the immune system one T cell at a time

Jo Vandesompele, PhD

Spotlight MF Jo Vandesompele

Jo Vandesompele at Ghent University discusses a deep dive into single-cell sequencing

Christophe Lancrin, PhD

Spotlight MF Christophe Lancrin

Christophe Lancrin on revealing new transcription factors using C1 and Biomark

Shyam Prabhakar, PhD

Spotlight MC SHYAM PRABHAKAR

Shyam Prabhakar explores signatures of patient survival and EMT in colorectal tumors

Simone Mayer, PhD

Spotlight MF Simone Mayer

Simone Mayer, PhD, explains how using multimodal analysis helped reveal new insights

Kelly Nudelman, PhD

Spotlight MF Kelly Nudelman and Tae-Hwi Schwantes

Kelly Nudelman and Tae-Hwi Schwantes-An discuss sample identification

Jonathan M. Irish, PhD

Combinatorial, single-cell approaches to explore the complexity of biologic systems

Scientist Michael Stubbington, PhD

A new single-cell sequencing tool brings fresh insight to functional T cell studies

CUSTOMER STORIES

Learn more about how our customers are leveraging Fluidigm technology

VIEW ALL

Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices